María del Rosario
García Campelo
Hospital Universitario Arnau de Vilanova
Lleida, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Arnau de Vilanova (4)
2022
-
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
Annals of Oncology, Vol. 33, Núm. 2, pp. 181-192
2017
-
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions
Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 341-356
-
Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions (Clin Transl Oncol, 10.1007/s12094-016-1535-8)
Clinical and Translational Oncology
-
Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists
Clinical and Translational Oncology, Vol. 19, Núm. 4, pp. 508-518